Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
VANCOUVER, British Columbia, Feb. 06, 2018 -- Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced the appointment of industry veteran Dr. Kaiji Hu to its scientific team as Research Scientist - Cell and Molecular Biology.
With over 20 years of Research and Development experience, Dr. Hu will be a part of leading Medipure’s Psoriasis and Fatty Liver Disease/NASH projects while supporting the mechanistic studies for Neuropathic Pain and Anxiety.
“We are excited to welcome Dr. Hu to the Medipure team,” said Boris Weiss, CEO of Medipure Pharmaceuticals. “He brings the immense expertise required for drug discovery and development, including biochemistry, cell biology and preclinical pharmacology. With his over 20 years of R&D experience and more than 20 publications and 2 patents to his credit, Dr. Hu is a great addition to the team.”
Dr. Kaiji Hu obtained his PhD in Biology from Simon Fraser University, and then joined the R&D team at a biotech company focusing on novel drug discovery for antibiotic, anti-cancer and anti-inflammatory applications.
From there he became a specialist in the Oncology Program at the University of British Columbia and the Family Research Institute, and coordinated the HCS core facility. He provided technical services including drug library screening and therapeutic target identification based on the HCS platform to biomedical research groups from both academia and the biopharma industry.
He continued his research on leukemia and drug compound screening at the Terry Fox Laboratory in the BC Cancer Research Center before taking his new position at Medipure Pharmaceuticals.
ABOUT MEDIPURE
Medipure Pharmaceuticals is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology.
Medipure Pharmaceuticals’ research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well understood by physicians, healthcare providers and prospective patients.
CONTACT:
Public Relations Contact:
CMW Media
Aaron Wood
Account Manager
858-264-6600
[email protected]
www.cmwmedia.com
